Literature DB >> 12029444

Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy.

M H Tsai1, Y C Shiau, C H Kao, Y Y Shen, C C Lin, C C Lee.   

Abstract

PURPOSE: The aim of this study was to evaluate the effectiveness of positron emission tomography (PET) using 18-fluoro-2-deoxyglucose (FDG) to detect recurrent nasopharyngeal carcinomas (NPC) when magnetic resonance imaging (MRI) findings are indeterminate. PATIENTS AND METHODS: After radiotherapy, 28 NPC patients with indeterminate MRI findings were included. MRI, FDG-PET, and biopsy were performed at least 4 months after radiotherapy and within 1 week. The final results were based on histopathologic findings and a clinical follow-up of at least 6 months.
RESULTS: For detecting recurrent NPC in indeterminate MRI findings, the sensitivity, specificity and accuracy of FDG-PET were 100.0%, 92.9% and 96.4%, respectively.
CONCLUSIONS: Based on these results, we can recommend FDG-PET for detecting recurrent NPC when MRI findings are indeterminate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029444     DOI: 10.1007/s00432-002-0341-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  7 in total

1.  Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging.

Authors:  Sheng-Chieh Chan; Shu-Hang Ng; Joseph Tung-Chieh Chang; Chien-Yu Lin; Yen-Chao Chen; Yu-Chen Chang; Cheng-Lung Hsu; Hung-Ming Wang; Chun-Ta Liao; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-19       Impact factor: 9.236

2.  18F-fluorodeoxyglucose positron emission tomography for predicting tumor response to radiochemotherapy in nasopharyngeal carcinoma.

Authors:  Meng Su; Liang Zhao; Hangping Wei; Ruifang Lin; Xuebang Zhang; Changlin Zou
Journal:  Strahlenther Onkol       Date:  2015-05-17       Impact factor: 3.621

Review 3.  Current treatment options for recurrent nasopharyngeal cancer.

Authors:  Carlos Suárez; Juan P Rodrigo; Alessandra Rinaldo; Johannes A Langendijk; Ashok R Shaha; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-24       Impact factor: 2.503

4.  Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.

Authors:  Peng Xie; Jin-Bo Yue; Han-Xi Zhao; Xin-Dong Sun; Li Kong; Zheng Fu; Jin-Ming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-20       Impact factor: 4.553

Review 5.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

Review 6.  Surveillance tools for detection of recurrent nasopharyngeal carcinoma: An evidence-based review and recommendations.

Authors:  Andrew Thamboo; Kim H Tran; Annette X Ye; Issraa Shoucair; Basel Jabarin; Eitan Prisman; Cathie Garnis
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2022-04-21

7.  Correlation of PET-CT, MRI and histopathology findings in the follow-up of patients with nasopharyngeal cancer.

Authors:  Semih Ak; Caner Kiliç; Samet Özlügedik
Journal:  Braz J Otorhinolaryngol       Date:  2020-01-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.